Last reviewed · How we verify
Platinum-based doublet chemotherapy
Platinum-based doublet chemotherapy uses two chemotherapy agents containing platinum to cross-link DNA and prevent cancer cell replication.
Platinum-based doublet chemotherapy uses two chemotherapy agents containing platinum to cross-link DNA and prevent cancer cell replication. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | Platinum-based doublet chemotherapy |
|---|---|
| Also known as | Chemotherapy |
| Sponsor | The First Hospital of Hebei Medical University |
| Drug class | Platinum-based chemotherapy doublet |
| Target | DNA (platinum-DNA adducts) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Platinum compounds (typically cisplatin or carboplatin) form covalent bonds with DNA, creating interstrand and intrastrand crosslinks that inhibit DNA replication and transcription, leading to cancer cell death. The doublet format combines a platinum agent with a second chemotherapy drug (commonly a taxane, gemcitabine, or pemetrexed) to enhance efficacy through synergistic mechanisms and broaden the spectrum of activity against tumor cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
- Gastric cancer
- Other solid tumors (regimen-dependent)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Alopecia
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC (PHASE3)
- The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients (PHASE2)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: